An editorial in the New England Journal of Medicine credits Science Corporation's PRIMA implant as the first treatment in clinical trials to successfully restore functional vision in patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD).[1] AMD is the leading cause of irreversible vision loss in adults in the US and other countries, affecting more than 5 million people worldwide.[1] Existing approved treatments to slow vision loss in patients with GA due to AMD only delay but do not stop the loss or improve vision.[1] PRIMA consists of a small wireless chip (2 mm x 2 mm x 30 µm) implanted under the retina in combination with special glasses that act as an array of artificial photoreceptors stimulating the remaining retinal cells.[1] This approach, unlike conventional therapies that only slow disease progression, has directly restored lost functional vision in GA patients in clinical trials.[1] GA is characterized by the loss of photoreceptors in the retina, and PRIMA solves this problem by directly stimulating the signal to the brain.[1]